ECM
VIRX

Elgethun Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Elgethun Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-38
Closed -$5K – 236
2016
Q4 		$5K Buy
+38
New +$5.29K ﹤0.01% 245

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Elgethun Capital Management's VIRX Position: Q1 2017 in Review

Elgethun Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2017, closing a stake of 38 shares — an estimated $5K sold.

Elgethun Capital Management first reported a position in VIRX in Q4 2016 and held it in 1 quarter. The position peaked at $5K in Q4 2016. 41 funds tracked by Wall St. Rank hold VIRX as of Q1 2017.

  • Elgethun Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Elgethun Capital Management sold 38 Viracta Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $5K.
  • Elgethun Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2016 and held it in 1 quarter.
  • Elgethun Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $5K in Q4 2016.
  • 41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2017.

Based on Elgethun Capital Management's 13F filing for Q1 2017, filed 11 May 2017.